Follow The Filings

BAX Baxter International

Health Care, filed as BAXTER INTL INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 2 Owners
  • #122
  • Max 3.7%
  • Master 0.18%
  • $300M
  • 1 add 1 reduce

In 2026 Q3 Murphy Pohlad added to Baxter International, while Greenhaven Associates trimmed.

Who owns this now

Largest portfolio weights among holders, up to 3.7% (Greenhaven Associates). Not free-float ownership.

  1. Greenhaven Associates Reduce 3.7%
  2. Murphy Pohlad Add 0.77%

Who owns BAX

Sorted by value, long equity only, as of 2026 Q3.

History
Greenhaven Associates 3.7% Reduce −13.2% 12,396,504 $298M History
Murphy Pohlad, Murphy Pohlad Asset Management 0.77%, was 0.44% Add +53.8% 92,868 $2.2M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BAX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BAX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 21 stock grants and 19 share withholdings for taxes.

Congress

4 members of Congress traded BAX in the last three years: 6 buys and 3 sales. 3 members listed it in 2025 annual reports.

All Congress trades
  1. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Oct 31, 2025 filed Nov 21, 2025
  2. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Oct 30, 2025 filed Nov 21, 2025
  3. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Oct 30, 2025 filed Nov 21, 2025
  4. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Sep 25, 2025 filed Oct 22, 2025
  5. Lisa C. McClain R-MI-9Spouse Sell $1K–$15K Aug 4, 2025 filed Sep 12, 2025
  6. Lisa C. McClain R-MI-9Spouse Buy $1K–$15K Jul 22, 2025 filed Aug 13, 2025

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated about 17 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $14.81B $10.64B $11.24B
Gross profit $4.98B $3.98B $3.38B
Gross margin * 33.6% 37.5% 30.1%
Net income $2.66B -$0.649B -$0.957B
Net margin * 17.9% -6.1% -8.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $9.6B $8.85B $6.87B
Total non-current assets * $18.68B $16.93B $13.18B
Total assets $28.28B $25.78B $20.06B
Total current liabilities $6.5B $6.51B $2.97B
Total non-current liabilities * $13.3B $12.25B $10.98B
Total equity $8.4B $6.96B $6.13B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $1.73B $1.02B $0.845B
Cash from investing $3.21B -$0.626B $2.84B
Cash from financing -$3.49B -$1.08B -$4.22B
Net change in cash $1.48B -$0.784B -$0.446B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.